Company profile: NodThera
1.1 - Company Overview
Company description
- Provider of NLRP3 inflammasome inhibitor therapeutics targeting inflammatory and neuroinflammatory diseases, including brain-penetrant candidates. Lead asset NT-0796 is in Phase Ib/IIa for Parkinson’s disease and cardiovascular risk in obese patients; NT-0249 is optimized for low-dose chronic inflammatory therapy, with additional CNS and peripheral candidates under development.
Products and services
- Neuro Development Candidate: A CNS-penetrant NLRP3 inflammasome inhibitor engineered to treat a broad range of neuroinflammatory diseases by targeting innate immune activation within the brain
- NT-0249: A brain-penetrant NLRP3 inflammasome inhibitor with optimized potency, architected for treating chronic inflammatory diseases and designed for low-dose therapy
- NT-0796: A brain-penetrant NLRP3 inflammasome inhibitor advancing through Phase Ib/IIa clinical evaluation for Parkinson’s disease and cardiovascular risk in obese patients, engineered to treat neuroinflammatory and peripheral inflammatory diseases
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to NodThera
Fresh Tracks Therapeutics
HQ: United States
Website
- Description: Provider of pharmaceutical therapeutics for autoimmune, inflammatory, and debilitating diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Fresh Tracks Therapeutics company profile →
Repertoire
HQ: United States
Website
- Description: Provider of clinical-stage immune medicines, offering the DECODE platform to identify TCRs and disease-relevant epitopes across all human HLAs; off-the-shelf TCR bispecific therapeutics that engage T cells via tumor-specific epitopes and an anti-CD3 moiety; mRNA cancer vaccines delivered via lipid nanoparticles; and mRNA tolerizing vaccines to induce T-cell anergy and expand regulatory T cells for autoimmune diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Repertoire company profile →
Phadia
HQ: Sweden
Website
- Description: Provider of complete blood test systems for the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; develops, manufactures and markets these systems, with more than 40 years of leadership in allergy testing.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Phadia company profile →
Kezar Life Sciences
HQ: United States
Website
- Description: Provider of drug discovery and development focused on protein homeostasis, offering Zetomipzomib (KZR-616), a selective immunoproteasome inhibitor for autoimmune diseases via immune modulation without direct immunosuppression, and KZR-261, a first-in-class Sec61 translocon inhibitor for advanced/metastatic solid tumors that blocks key secreted proteins.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Kezar Life Sciences company profile →
DBV Technologies
HQ: France
Website
- Description: Provider of investigational epicutaneous immunotherapy products for food allergies and other immunological disorders via the Viaskin technology platform, including Viaskin Peanut, a patch delivering small amounts of peanut protein to the skin. Also developing Viaskin-based approaches for other food allergies, an investigational diagnostic for non-IgE-mediated milk allergy, and non-invasive vaccine delivery.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full DBV Technologies company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for NodThera
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to NodThera
2.2 - Growth funds investing in similar companies to NodThera
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for NodThera
4.2 - Public trading comparable groups for NodThera
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →